Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. (NASDAQ: CELU) is a regenerative and aging-related cellular medicine company whose news flow reflects developments across placental-derived biomaterial products, cell therapies, financing, and regulatory milestones. As a Nasdaq-listed issuer, Celularity regularly reports corporate updates, clinical data, partnerships, and capital markets transactions that are relevant to investors and observers of the regenerative medicine and longevity sectors.
News about Celularity often covers its advanced biomaterial products and wound care franchise, including updates on Biovance and Biovance 3L human amniotic membrane allografts and related reimbursement and coverage policies. The company has commented on Centers for Medicare & Medicaid Services decisions affecting skin substitute products and has highlighted real-world evidence from clinical use of its wound care products. These items can influence perceptions of the company’s commercial trajectory in chronic wound management.
Another key category of Celularity news involves its placenta-derived cell therapy programs, such as PDA-002. The company has announced peer-reviewed Phase 2 clinical trial results in diabetic foot ulcers complicated by peripheral artery disease and has discussed how state-level laws, particularly in Florida, may enable physician-directed use of certain stem cell therapies in orthopedics, wound care, and pain management. Such updates provide insight into the clinical and regulatory landscape for its investigational products.
Celularity’s press releases also address strategic partnerships and corporate structure. Examples include collaborations with Fountain Life in longevity-focused centers and with DefEYE, Inc. in ophthalmic biologics, as well as internal restructuring into distinct operating subsidiaries. In addition, the company reports on financings, debt restructuring, Nasdaq listing rule matters, and preferred stock or warrant issuances. For readers tracking CELU, this news page aggregates these developments so they can follow how Celularity’s placental-derived platform, commercial units, and capital structure evolve over time.
Celularity (NASDAQ: CELU) commented on CMS’s December 24, 2025 withdrawal of skin substitute Local Coverage Determinations (LCDs) that had been due to take effect January 1, 2026.
CMS withdrew the LCDs while leaving in place a new Medicare payment rate of $127.28 per square centimeter for skin substitute applications effective January 1, 2026. The withdrawn LCDs would have kept Celularity’s Biovance and Biovance 3L eligible; CMS’s action removed Medicare coverage for 158 other skin substitute products. CEO Dr. Robert J. Hariri highlighted real-world evidence (including reduced steroid use in about half of treated patients) and cited Celularity’s scalable GMP/GTP manufacturing in Florham Park, NJ as compatible with the new reimbursement.
Celularity (Nasdaq: CELU) announced closing of financing transactions on Dec 22, 2025 that provided $10.0 million in gross proceeds with up to an additional $2.0 million available subject to closing conditions. The financing combines a $7.0 million senior secured term loan (first-priority lien on substantially all assets) and secured convertible notes with aggregate commitments up to $5.0 million, convertible at $1.66 per share. Celularity also issued five-year warrants for 3,707,657 Class A shares exercisable from June 19, 2026 at $2.00 per share. The company said proceeds will support operations, strategic initiatives and its longevity-focused platform.
Celularity (Nasdaq: CELU) entered binding term sheets for financing expected to provide up to $12.0 million in private capital to support priorities in longevity and preservation of human performance.
Under the term sheets, Celularity expects initial proceeds of $10.0 million, comprising a $7.0 million senior secured term loan with a first‑priority lien on substantially all assets and secured convertible notes of up to $5.0 million convertible at $1.66 per share. The company will also issue warrants equal to 33% of the as‑converted principal, exercisable after six months at $2.00 per share. Transactions are private placements and contingent on definitive agreements.
Celularity (Nasdaq: CELU) announced a strategic partnership with DefEYE, including an exclusive sublicense and pricing arrangement tied to Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equity round.
DefEYE, formed from Verséa Ophthalmics leadership, reported ~70% sales growth in 2024 and plans to use funding to launch decellularized ophthalmic biologics including Biovance, Biovance 3L, Interfyl and related R&D. Celularity will be DefEYE’s exclusive contract manufacturer for the ophthalmic portfolio and retains the right to name one of five board members.
Celularity (Nasdaq: CELU) announced peer-reviewed publication of its Phase 2 trial of PDA-002, a placenta-derived cell therapy for diabetic foot ulcers (DFU) with and without peripheral artery disease (PAD), in the International Wound Journal on October 14, 2025.
The multi-center, randomized, double-blind trial enrolled 159 patients across 35 US sites. Patients received two intramuscular doses (3×10^6, 10×10^6, or 30×10^6 cells) or placebo. In the PAD subgroup, the 3×10^6 dose achieved 38.5% complete wound closure versus 22.6% for placebo. PDA-002 showed faster, more sustained healing, fewer new gangrene and foot infections, and no serious treatment-related safety signals through two years.
Celularity (Nasdaq: CELU), a regenerative medicine company, has filed its Q1 and Q2 2025 Form 10-Q reports and regained compliance with Nasdaq Listing Rule 5250(c)(1). The company has made significant progress in addressing financial challenges, including the retirement of $32.0 million in senior secured debt plus $9.6 million in unpaid interest.
Under CEO Robert J. Hariri's leadership, Celularity has implemented strategic changes including an internal restructuring with dedicated operating subsidiaries for each business unit. The company faced working capital pressures in H1 2025 due to wound care product reimbursement uncertainty and delayed cash collections. Management now believes Celularity is positioned to access traditional working capital facilities to support wound care sales growth and advance its three late-stage 510(k) pipeline products.
Celularity (NASDAQ:CELU), a regenerative and cellular medicine company, announced receiving a notice from Nasdaq on August 21, 2025, regarding its failure to file the Q2 2025 Form 10-Q. This marks the company's second delayed quarterly filing, following the Q1 2025 Form 10-Q.
The company is currently non-compliant with Nasdaq Listing Rule 5250(c)(1), though this notice does not immediately affect CELU's listing status. Nasdaq has given Celularity until September 5, 2025 to update its compliance plan, with a final deadline of November 17, 2025 to file all delinquent reports.
Celularity (NASDAQ:CELU) has completed a significant balance sheet restructuring, successfully retiring all $41.6 million in senior secured debt, including $32.0 million in principal and $9.6 million in unpaid interest. The company executed this through an Asset Purchase Agreement with Celeniv Pte. Ltd., selling its intellectual property assets while maintaining exclusive licensing rights for 5 years with renewal options.
The transaction included a $33.8 million consideration used to retire debt from RWI and a Promissory Note from Mr. Lim. Additionally, Celularity completed an internal restructuring, creating six wholly-owned subsidiaries for its commercial units: biomaterials, longevity cell therapy, biobanking, contract manufacturing, discovery & development, and asset holding.
Celularity (Nasdaq: CELU) has formed a strategic partnership with Fountain Life to provide stem cell therapy products in Florida, leveraging a new state law effective July 1, 2025. The legislation allows qualified physicians to administer stem cell treatments for orthopedic conditions, wound healing, and pain management without FDA IND approval.
Fountain Life operates four longevity centers, including two in Florida (Naples and Lake Nona-Orlando), with Miami opening soon. Celularity will supply clinical-grade, placental-derived stem cells from its FDA-registered facility in New Jersey, offering immediate availability for physician-directed use under the new regulatory framework.
Celularity (Nasdaq: CELU), a regenerative and cellular medicine company, welcomes a new Florida law effective July 1, 2025, that authorizes physicians to provide investigational stem cell therapies for orthopedics, wound care, and pain management. The legislation permits the use of non-FDA approved stem cell treatments under strict safety and ethical guidelines.
The law requires stem cells to be sourced from FDA-registered and certified/accredited facilities that comply with Good Manufacturing Practices. Physicians must obtain patient informed consent before administering treatments. Celularity, operating an FDA-registered facility with extensive stem cell inventory, is positioned to supply ethically sourced placenta-derived stem cells for these authorized therapies.
The company, through its predecessor Anthrogenesis Corporation, pioneered the discovery of placental stem cell recovery methods in 2001, which was acknowledged by President George W. Bush. The Florida Medical Association was actively involved in crafting the legislation to balance public protection and physician regulation.
FAQ
What is the current stock price of Celularity (CELU)?
What is the market cap of Celularity (CELU)?
